ADMA Biologics Faces Securities Class Action Deadline

The Gross Law Firm initiated the action following claims that ADMA Biologics misled the market during the specified class period. The complaint alleges that the company utilized channel stuffing to artificially inflate revenue figures and failed to disclose critical related-party transactions. These actions, according to the filing, obscured the company’s true financial health and operational stability.

Shareholders who incurred losses during this window are eligible to participate in the litigation. Registering with the firm provides investors with portfolio monitoring and case status updates. Participation does not require an investor to serve as a lead plaintiff, and the firm notes that there is no cost or obligation for those joining the action. The case centers on the assertion that the company’s public statements lacked a reasonable basis, ultimately harming shareholders who relied on the accuracy of these disclosures.